Table 2 Therapeutic responses to methotrexate
From: Randomized controlled trial design in rheumatoid arthritis: the past decade
|  |  |  | ACR ≥ 20 responses at | |
|---|---|---|---|---|
Study/Trial | Mean disease duration | Median MTX dose (mg/week) | 12 months | 24 months |
Haagsma, et al. [74] | 3 months | 10 | 71% | NR |
Möttönen, et al. [57] | 8 months | 10 | 78% | 84% |
11 months | 18a | 65% | 59% | |
MN 302 [15] | 3.8 years | 10 | 65%b | 72% |
US 301 [5] | 6.5 years | 15a | 46%b | 67% |
ASPIRE [10] | 7 months | 19a | 54%b | NR |
TEMPO [13] | 6.6 years | 17a | 75% | 71% |
PREMIER [11] | 8 to 9 months | 16a | 63%b | 56% |